WhatsApp used in research, but is this ethical?

By HEOR Staff Writer

March 15, 2023

Globally, WhatsApp Messenger has emerged as one of the world’s fastest-growing MIM applications. It has particularly high penetration rates in India, Indonesia, Malaysia, Brazil and South Africa.

The sub-Saharan African region is characterized by mixed migration flows and multiple health challenges, due to the inequalities experienced in access to healthcare disproportionately affect many groups including migrants and mobile populations. Given the existing structural factors impeding access to healthcare, coupled with high rates of mobile telephone use across the sub-Saharan African region; mobile phones are consistently recognized as having great potential for improving access to healthcare in this context.

WhatsApp was largely used in one of two ways for health research; to send hyperlinks to online surveys, or to deliver and evaluate, either an intervention designed for healthcare users or a communication programme for healthcare providers.

Challenges include efforts taken to ensure privacy, confidentiality and anonymity when using WhatsApp as a data collection tool; significant gender divide in access to mobile phones, with men being far more likely to have access to a device than women; features in WhatsApp that could potentially allow some encrypted messages to be read by unintended recipients, compounding the possible breaches of WhatsApp data.

Reference url

Recent Posts

Harmonizing Non-Clinical Evaluation of Microbiome Medicinal Products in the EU

By João L. Carapinha

March 4, 2026

EMA's Push for Microbiome Medicinal Products Guidance EMA's Non-Clinical Working Party has drafted a concept paper, adopted by CHMP on 16 February 2026, proposing a reflection paper to guide non-clinical development of microbiome...
Tirzepatide Cost Effectiveness: A Winning Strategy for Type 2 Diabetes Management

By João L. Carapinha

March 3, 2026

Tirzepatide Cost Effectiveness in UK T2D Care Evaluating tirzepatide cost effectiveness reveals significant advantages over semaglutide 1 mg for patients with type 2 diabetes (T2D) inadequately controlled on metformin, based on a
CHMP February 2026 Approvals: New Breakthroughs in Medicines and Biosimilars
CHMP February 2026 Approvals: 12 New Medicines and Biosimilars Advance The CHMP Febru...